The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
David M. G. Halpin
Tuberc Respir Dis. 2018;81(1):13-18.   Published online 2017 Dec 29     DOI: https://doi.org/10.4046/trd.2017.0098
Citations to this article as recorded by Crossref logo
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies
Roland Buhl, Dave Singh, Alberto de la Hoz, Wenqiong Xue, Gary T. Ferguson
Advances in Therapy.2020; 37(8): 3485.     CrossRef
A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
Roland Buhl, Michael Dreher, Stephanie Korn, Christian Taube, Christian Stock, Christoph M Zehendner, Anke Kondla, Claus F Vogelmeier
International Journal of Chronic Obstructive Pulmonary Disease.2020; Volume 15: 2601.     CrossRef
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
Eric Derom, Guy G. Brusselle, Guy F. Joos
Therapeutic Advances in Respiratory Disease.2019; 13: 175346661984342.     CrossRef
Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease
Swetha R Palli, Ami R Buikema, Mary DuCharme, Monica Frazer, Shuchita Kaila, Timothy Juday
Journal of Comparative Effectiveness Research.2019; 8(15): 1299.     CrossRef